收藏切换
Key Technical Considerations in the Drugs Design of Clinical Trials for Delaying the Progression of Chronic Kidney Disease
收藏切换
PDF
Jiejing LI, Na WANG, Chongqi TANG, Shuiqiang WANG, Songmei XIE*
Chinese Pharmaceutical Journal | 2024, 59(14) : 1273 - 1277
Less
收藏切换
Chinese Pharmaceutical Journal | 2024, 59(14): 1273-1277
Key Technical Considerations in the Drugs Design of Clinical Trials for Delaying the Progression of Chronic Kidney Disease
Full
Jiejing LI, Na WANG, Chongqi TANG, Shuiqiang WANG, Songmei XIE*
Affiliations
  • Center for Drug Evaluation,National Medical Products Administration, Beijing 100076, China
Published: 2024-07-22 doi: 10.11669/cpj.2024.14.001
Outline
收藏切换

OBJECTIVE To explore the key technical considerations in the drugs design of clinical trials for delaying the progression of chronic kidney disease. METHODS By reviewing domestic and foreign literature, and considering the characteristics of the disease, drug development and review experience, the important design considerations for clinical trials evaluating drugs that delay the progression of chronic kidney disease were suggested in this article. RESULTS and CONCLUSION We recommend an overall trial design that incorporates randomization, double-blinding, and placebo/standard treatment as control measures. The study population should be representative of a wide range of individuals who reflect the intended objectives of the trial. Inclusion criteria and efficacy evaluation should take into account etiology, staging, risk factors for disease progression, and combined treatments. We suggest the composite endpoints based on clinical events as primary efficacy endpoints,while the average change rate in glomerular filtration rate is recommended for early or slowly progressing chronic kidney disease cases. Safety evaluation indicators should not only adhere to general standards but also consider potential safety issues related to investigational drugs as well as safety signals associated with natural disease progression by setting corresponding safety assessment parameters for underlying diseases.

chronic kidney disease  /  clinical trials  /  slow progression  /  drug development
Jiejing LI, Na WANG, Chongqi TANG, Shuiqiang WANG, Songmei XIE. Key Technical Considerations in the Drugs Design of Clinical Trials for Delaying the Progression of Chronic Kidney Disease[J]. Chinese Pharmaceutical Journal, 2024 , 59 (14) : 1273 -1277 . DOI: 10.11669/cpj.2024.14.001
Year 2024 volume 59 Issue 14
PDF
197
93
Cite this Article
BibTeX
Article Info
doi: 10.11669/cpj.2024.14.001
  • Receive Date:2024-03-04
  • Online Date:2026-01-14
  • Published:2024-07-22
Article Data
Affiliations
History
  • Received:2024-03-04
Affiliations
    Center for Drug Evaluation,National Medical Products Administration, Beijing 100076, China
References
Share
https://castjournals.cast.org.cn/joweb/zgyxzz/EN/10.11669/cpj.2024.14.001
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT